22:55 , Nov 15, 2018 |  BC Innovations  |  Product R&D

Tempest takes PPAR alpha into cancer

Tempest Therapeutics Inc.’s first data from its preclinical PPARα program gave it the support it was looking for to repurpose the cardiovascular target for cancer. Tapping into the emerging field of cancer immuno-metabolism, Tempest is...
18:16 , Nov 9, 2018 |  BC Week In Review  |  Clinical News

Early data for Enyo's HBV, NASH candidate tee up Phase II

Enyo Pharma S.A. (Lyon, France) said once-daily oral EYP001 for four weeks was well tolerated with no off-target effects or serious adverse events reported in a Phase Ib trial to treat chronic HBV infection. The...
17:53 , Nov 9, 2018 |  BC Week In Review  |  Company News

J&J adds to lung cancer arsenal with Yuhan deal

Janssen Pharmaceuticals Inc. licensed non-small cell lung cancer (NSCLC) compound lazertinib from Yuhan Corp. (KSE:000100) for $50 million up front and up to $1.2 billion in development and commercial milestones, giving Johnson & Johnson (NYSE:JNJ)...
22:41 , Nov 8, 2018 |  BC Innovations  |  Product R&D

JLABS seeks lung cancer solutions in Shanghai

As Johnson & Johnson gears up to launch its Shanghai JLABS site early next year, the incubator’s head, Sharon Chan, has pegged lung cancer as one of the first priorities. Chan sees opportunity in China...
00:15 , Nov 6, 2018 |  BC Extra  |  Company News

J&J adds to lung cancer arsenal with Yuhan deal

Janssen Pharmaceuticals Inc. licensed non-small cell lung cancer (NSCLC) compound lazertinib from Yuhan Corp. (KSE:000100) for $50 million up front and up to $1.2 billion in development and commercial milestones, giving Johnson & Johnson (NYSE:JNJ)...
02:27 , Nov 3, 2018 |  BioCentury  |  Product Development

New partners for NASH

Pharmas are loading up their NASH portfolios expecting that addressing the full disease spectrum will require combinations, though the field lacks the tools to sort the different mechanisms on offer strategically. Meanwhile, at least three...
19:23 , Oct 26, 2018 |  BC Week In Review  |  Financial News

89Bio, a NASH start-up with Teva ties, debuts with $60M

89Bio Ltd. (San Francisco, Calif.) will use its $60 million series A financing to develop therapeutics for non-alcoholic steatohepatitis and other liver and metabolic diseases. The financing was co-led by OrbiMed Israel, OrbiMed US and...
22:55 , Oct 25, 2018 |  BC Innovations  |  Targets & Mechanisms

Blueprint for selectivity

Blueprint Medicines Corp. is making the jump from cancer to rare disease with an inhibitor for the rare pediatric bone disease FOP that sets the company up against at least two competitors further ahead in...
22:52 , Oct 25, 2018 |  BC Extra  |  Financial News

89Bio, a NASH start-up with Teva ties, debuts with $60M

89Bio Ltd. (San Francisco, Calif.) will use its $60 million series A financing to develop therapeutics for non-alcoholic steatohepatitis and other liver and metabolic diseases. The financing was co-led by OrbiMed Israel, OrbiMed US and...
02:10 , Oct 20, 2018 |  BioCentury  |  Product Development

CVOT damage in diabetes

As FDA reconsiders its requirement for cardiovascular outcomes trials of new diabetes candidates, it’s clear that the development of new therapies has slowed since it was implemented. In December 2008, FDA issued guidance requiring diabetes...